Compare Roblox Corp (RBLX) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Sanofi SA — how do they compare? Roblox Corp trades at $44.6 (market cap $32.02B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 3.2× Roblox Corp's market cap, and Sanofi SA pays a 5.61% dividend while Roblox Corp pays none. Which is the better fit depends on your goals.
| RBLX | SNY | |
|---|---|---|
Market Cap | $32.02B | $104.06B |
Sector | Media | Health |
52-Week High | $141.56 | $52.34 |
52-Week Low | $35.54 | $41.33 |
Enterprise Value | $30.84B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RBLX trades at $44.82, up 3.49% today, near the consensus price target of $45.71. The stock shows bullish technical signals with strong support at $43 and resistance at $46. Revenue growth is robust, rising to $4.89B in 2025, but net losses persist at -$1.07B. Recent news highlights regulatory scrutiny in the EU and Australia over child safety, alongside positive economic impact from creator earnings.
Outlook remains mixed: strong revenue growth and cash flow improvement support long-term potential, but profitability challenges and regulatory risks weigh on sentiment. Analysts are divided, with 44.7% recommending buy. The key catalyst is achieving sustained profitability amid expanding user engagement.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
